The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group
Open accessAbstract
Purpose: Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients. Minimal residual disease (MRD) levels during the first months predict outcome and may select patients for therapy reduction or intensification. Methods: Patients 1 to 18 years old with ALL were stratified on the basis of MRD levels after the first and second course of chemotherapy. Thereafter, therapy was substantially reduced in patients with undetectable MRD (standard risk) and intensified in patients with intermediate (medium risk) and high (high risk) levels of MRD. Seven hundred seventy-eight consecutive patients were enrolled. The method of analysis was intention-to-treat. Outcome was compared with historical controls. Results: In MRD-based standard-risk patients, the 5-year event-free survival (EFS) rate was 93% (SE 2%), the 5-year survival rate was 99% (SE 1%), and the 5-year cumulative incidence of relapse rate was 6% (SE 2%). The safety upper limit of number of observation years was reached and therapy reduction was declared safe. MRD-based medium-risk patients had a significantly higher 5-year EFS rate (88%, SE 2%) with therapy intensification (including 30 weeks of asparaginase exposure and dexamethasone/vincristine pulses) compared with historical controls (76%, SE 6%). Intensive chemotherapy and stem cell transplantation in MRD-based high-risk patients resulted in a significantly better 5-year EFS rate (78%, SE 8% v 16%, SE 8% in controls). Overall outcome improved significantly (5-year EFS rate 87%, 5-year survival rate 92%, and 5-year cumulative incidence of relapse rate 8%) compared with preceding Dutch Childhood Oncology Group protocols. Conclusion: Chemotherapy was substantially reduced safely in one-quarter of children with ALL who were selected on the basis of undetectable MRD levels, without jeopardizing the survival rate. Outcomes of patients with intermediate and high levels of MRD improved with therapy intensification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440
Self-citationDeletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Sequential Tests of Statistical Hypotheses
Wald, A. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-0919-5_18 · Cited by 1,345
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
van Dongen, J. J., Seriu, T., Panzer-Grümayer, E. R., Biondi, A., Pongers-Willemse, M. J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W. A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04058-6 · Cited by 952
Self-citationDen Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., Van Zutven, L. J., Beverloo, H. B., Van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 930
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 865
Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248146 · Cited by 785
Self-citationClinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B., Vilmer, E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390904 · Cited by 768
Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M., Hovi, L., LeBlanc, T., Szczepanski, T., Ferster, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61126-x · Cited by 652
Self-citationL‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569
Self-citationmstate: An R Package for the Analysis of Competing Risks and Multi-State Models
Wreede, L. C. D., Fiocco, M., & Putter, H. (2011) · Journal of Statistical Software · doi:10.18637/jss.v038.i07 · Cited by 478
Self-citationVora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
Coustan-Smith, E., Behm, F. G., Sanchez, J., Boyett, J. M., Hancock, M. L., Raimondi, S. C., Rubnitz, J. E., Rivera, G. K., Sandlund, J. T., Pui, C.-H., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10295-1 · Cited by 447
Schrappe, M., Valsecchi, M. G., Bartram, C. R., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B., et al. (2011) · Blood · doi:10.1182/blood-2011-03-338707 · Cited by 435
Self-citationBorowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633685 · Cited by 362
Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grümayer, R., van der Velden, V, Fischer, S., Stanulla, M., Basso, G., Niggli, F. K., Schäfer, B. W., et al. (2008) · Leukemia · doi:10.1038/leu.2008.5 · Cited by 361
Self-citationBiondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70377-7 · Cited by 330
Self-citationde Bont, J. M., Holt, B. V. D., Dekker, A. W., van der Does-van den Berg, A., Sonneveld, P., & Pieters, R. (2004) · Leukemia · doi:10.1038/sj.leu.2403538 · Cited by 323
Self-citationVora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70243-8 · Cited by 302
van der Veer, A., Waanders, E., Pieters, R., Willemse, M. E., Van Reijmersdal, S. V., Russell, L. J., Harrison, C. J., Evans, W. E., van der Velden, V. H. J., Hoogerbrugge, P. M., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462358 · Cited by 289
Self-citationIKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
Kuiper, R. P., Waanders, E., van der Velden, V. H. J., van Reijmersdal, S. V., Venkatachalam, R., Scheijen, B., Sonneveld, E., van Dongen, J. J. M., Veerman, A. J. P., van Leeuwen, F. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.87 · Cited by 268
Self-citationBuitenkamp, T. D., Izraeli, S., Zimmermann, M., Forestier, E., Heerema, N. A., van den Heuvel-Eibrink, M. M., Pieters, R., Korbijn, C. M., Silverman, L. B., Schmiegelow, K., et al. (2014) · Blood · doi:10.1182/blood-2013-06-509463 · Cited by 248
Self-citationVeerman, A. J., Kamps, W. A., van den Berg, H., van den Berg, E., Bökkerink, J. P., Bruin, M. C., van den Heuvel-Eibrink, M. M., Korbijn, C. M., Korthof, E. T., van der Pal, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70228-1 · Cited by 245
Self-citationPieters, R., den Boer, M., Durian, M., Janka, G., Schmiegelow, K., Kaspers, G., van Wering, E., & Veerman, A. (1998) · Leukemia · doi:10.1038/sj.leu.2401129 · Cited by 245
Self-citationLoh, M. L., Zhang, J., Harvey, R. C., Roberts, K., Payne-Turner, D., Kang, H., Wu, G., Chen, X., Becksfort, J., Edmonson, M., et al. (2013) · Blood · doi:10.1182/blood-2012-04-422691 · Cited by 177
Woerden, N. L. R.-V., Pieters, R., Loonen, A. H., Hubeek, I., van Drunen, E., Beverloo, H. B., Slater, R. M., Harbott, J., Seyfarth, J., van Wering, E. R., et al. (2000) · PubMed · Cited by 166
Self-citationvan der Velden, V. H. J., Panzer‐Grümayer, E. R., Cazzaniga, G., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404535 · Cited by 151
Matloub, Y., Bostrom, B., Hunger, S. P., Stork, L. C., Angiolillo, A. L., Sather, H. N., La, M., Gastier, J. M., Heerema, N. A., Sailer, S. L., et al. (2011) · Blood · doi:10.1182/blood-2010-12-322909 · Cited by 148
Kamps, W., Bökkerink, J. P. M., Hakvoort-Cammel, F., Veerman, A. J. P., Weening, R. S., van Wering, E., van Weerden, J., Hermans, J., Slater, R. M., van den Berg, E., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402489 · Cited by 135
Yeoh, A. E. J., Ariffin, H., Chai, E. L. L., Kwok, C. S. N., Chan, Y. H., Kuperan, P., Campana, D., Tan, P. L., Chan, M. Y., Kham, S. K. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5936 · Cited by 135
Conter, V., Valsecchi, M. G., Silvestri, D., Campbell, M., Dibar, E., Magyarosy, E., Gadner, H., Starý, J., Benoît, Y., Zimmermann, M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60073-7 · Cited by 115
Buitenkamp, T., Pieters, R., Gallimore, N. E., van der Veer, A., Meijerink, J. P. P., Beverloo, H. B., Zimmermann, M., de Haas, V., Richards, S. M., Vora, A. J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.84 · Cited by 109
Self-citationKamps, W. A., Bökkerink, J. P. M., Hählen, K., Hermans, J., Riehm, H., Gadner, H., Schrappe, M., Slater, R. M., Ruiter, E. V. D. B.-D., Smets, L. A., et al. (1999) · PubMed · Cited by 107
Biology and Treatment of Acute Lymphoblastic Leukemia
Pieters, R., & Carroll, W. L. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.014 · Cited by 64
Self-citationA new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia
Vlierberghe, P. V., Meijerink, J. P. P., Lee, C., Ferrando, A. A., Look, A. T., van Wering, E. R., Beverloo, H. B., Aster, J. C., & Pieters, R. (2006) · Leukemia · doi:10.1038/sj.leu.2404247 · Cited by 53
Self-citationChauvenet, A. R., Martin, P. L., Devidas, M., Linda, S. B., Bell, B. A., Kurtzberg, J., Pullen, J., Pettenati, M. J., Carroll, A. J., Shuster, J. J., et al. (2007) · Blood · doi:10.1182/blood-2006-12-061689 · Cited by 52
Stams, W. A. G., den Boer, M. L., Beverloo, H. B., Meijerink, J. P. P., van Wering, E. R., Janka-Schaub, G. E., & Pieters, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1829 · Cited by 27
Self-citation
Cited by
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
Toft, N., Birgens, H., Abrahamsson, J., Griškevičius, L., Hallböök, H., Heyman, M., Klausen, T. W., Jónsson, Ó., Palk, K., Pruunsild, K., et al. (2018) · Leukemia · doi:10.1038/leu.2017.265 · Cited by 409
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C.-H. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 291
Jeha, S., Pei, D., Choi, J., Cheng, C., Sandlund, J. T., Coustan-Smith, E., Campana, D., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01692 · Cited by 266
Metadata
- Authors
- Pieters, R., de Groot-Kruseman, H., Van der Velden, V., Fiocco, M., van den Berg, H., de Bont, E., Egeler, R. M., Hoogerbrugge, P., Kaspers, G., Van der Schoot, E., De Haas, V., & Van Dongen, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-08-01
- Volume
- 34
- Issue
- 22
- Pages
- 2591-2601
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2413038045
- Cited by
- 366
- References
- 40
- FWCI
- 27.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.